Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission

NCT01885689 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT01885689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01885689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 10, 2014
Completion date
September 21, 2026
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute lymphoblastic leukemia in remission, adult acute myeloid leukemia in remission, chronic myelomonocytic leukemia, myelodysplastic syndrome, secondary myelodysplastic syndrome, therapy-related myelodysplastic syndrome